An observational study in Irritable Bowel Syndrome (IBS), sponsored by AstraZeneca. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2018-11-07.
Sponsored by AstraZeneca · Observational
The primary objective of this study is to estimate the overall prevalence of IBS medically diagnosed and diagnosed using Rome III or IV criteria in GI adult outpatients in China.
This is a multicentre, nationwide and cross-sectional study carried out in China, covering 30 sites and 3000 patients totally. As for the ratio of tertiary to secondary general hospitals is approximately 1:4 in China, 6 tertiary and 24 secondary hospitals will be randomly selected in this study.To adapt the representativeness of the data with the operational feasibility, 30 tertiary and 120 secondary hospitals will be randomly selected over the 6 geographic regions (north, northeast, east, south central, southwest and northwest). Among those, 1 tertiary and 4 secondary hospitals in each region will be further selected based on GI department setup, willingness to participate in the study, capability and primary investigator's consideration. Within participated hospitals, subjects will be enrolled consecutively from all the outpatients of GI department to minimize selection bias. 3000 subjects will be allocated to tertiary and secondary hospitals with a ratio of 1:1. In general, 250 subjects will be enrolled from tertiary hospitals and 250 subjects will be enrolled from secondary hospitals for each region. During the subject enrolment, the investigator will firstly explain the purpose of the study to consecutive GI patients and written informed consents will be obtained. Then qualified patients will be given a questionnaire and finish it during waiting time. After receiving questionnaires, IBS diagnosis will be made by investigators based on Rome III or Rome IV IBS diagnostic criteria. Subjects will be identified as medically diagnosed with IBS if they have been diagnosed by their clinicians. And subjects will be classified as IBS sufferers without medical diagnosis if they satisfy Rome III or Rome IV diagnostic criteria and have not received IBS diagnosis from physicians. For IBS patients, either medically diagnosed or diagnosed with IBS criteria, investigators will collect all the information on demographic features, disease characteristics and current treatment status. For non-IBS patients, only demographic information will be collected.
1,062 studies on the registry are indexed under Irritable Bowel Syndrome; 190 are open to participants now.
This study's enrollment of 3,000 is above the median of 150 across 178 observational studies indexed under Irritable Bowel Syndrome.
Browse Irritable Bowel Syndrome studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
gastroenterological adult outpatients
Exclusion Criteria:
IBS prevalence in GI adult outpatients in China
Overall prevalence of IBS medically diagnosed and diagnosed using Rome III or IV criteria in GI adult outpatients in China.
Time frame: one day
Overall and subgroups' prevalence of medically diagnosed IBS in GI adult outpatients
Overall prevalence and prevalence of IBS-C, D, M, U of medically diagnosed IBS adult outpatients.
Time frame: one day
Overall and subgroups' prevalence of IBS sufferers in GI adult patients without medical diagnosis
Overall prevalence and prevalence of IBS-C, D, M, U of IBS sufferers in GI adult patients without medical diagnosis
Time frame: one day
Identify demographic features of IBS and non-IBS outpatients
Demographic features of IBS and non-IBS outpatients: age, gender, occupation, use of smoking and alcohol, diet, sleeping habit
Time frame: one day
Identify disease characteristics of IBS outpatients
Disease characteristics of IBS outpatients: reason for visit to clinic, time of symptoms occur and diagnosis, previous diagnosis, bothersomeness of symptoms, frequency of symptoms, severity of symptoms, absence of work
Time frame: one day
Assess the current treatment status of IBS outpatients
Current treatment status: hospital visit frequency, previous medicine use, concomitant medications, treatment efficacy, treatment satisfaction, cost of therapy
Time frame: one day
Estimate the overall and subgroups' prevalence of IBS diagnosed by Rome III criteria in GI adult patients
Overall prevalence and prevalence of IBS-C,D,M,U of IBS diagnosed by Rome III criteria in GI adult outpatients in China
Time frame: one day
Estimate the overall and subgroups' prevalence of IBS diagnosed by Rome IV criteria in GI adult patients
Overall prevalence and prevalence of IBS-C,D,M,U of IBS diagnosed by Rome IV criteria in GI adult outpatients in China.
Time frame: one day
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca